CABA vs. ALEC, VALN, PROK, ALLO, HUMA, TSHA, FATE, CCCC, EDIT, and VYGR
Should you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Alector (ALEC), Valneva (VALN), ProKidney (PROK), Allogene Therapeutics (ALLO), Humacyte (HUMA), Taysha Gene Therapies (TSHA), Fate Therapeutics (FATE), C4 Therapeutics (CCCC), Editas Medicine (EDIT), and Voyager Therapeutics (VYGR). These companies are all part of the "biological products, except diagnostic" industry.
Cabaletta Bio (NASDAQ:CABA) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership.
Cabaletta Bio has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
In the previous week, Alector had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 2 mentions for Alector and 1 mentions for Cabaletta Bio. Alector's average media sentiment score of 1.34 beat Cabaletta Bio's score of 0.49 indicating that Alector is being referred to more favorably in the news media.
Cabaletta Bio currently has a consensus price target of $34.33, suggesting a potential upside of 184.22%. Alector has a consensus price target of $14.86, suggesting a potential upside of 186.26%. Given Alector's higher possible upside, analysts clearly believe Alector is more favorable than Cabaletta Bio.
Alector received 69 more outperform votes than Cabaletta Bio when rated by MarketBeat users. However, 69.44% of users gave Cabaletta Bio an outperform vote while only 60.25% of users gave Alector an outperform vote.
Cabaletta Bio has a net margin of 0.00% compared to Alector's net margin of -134.34%. Cabaletta Bio's return on equity of -40.83% beat Alector's return on equity.
Cabaletta Bio has higher earnings, but lower revenue than Alector. Cabaletta Bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
85.8% of Alector shares are held by institutional investors. 9.9% of Cabaletta Bio shares are held by company insiders. Comparatively, 14.0% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Alector beats Cabaletta Bio on 10 of the 17 factors compared between the two stocks.
Get Cabaletta Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cabaletta Bio Competitors List
Related Companies and Tools
